REGN supply chain intelligence for Regeneron Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Regeneron Pharmaceuticals, Inc. (REGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SANOFI | SANOFI | 90% | The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies, which currently consists of Dupixent ® (dupilumab), Ke… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 85% | Reciprocal relationship from ALNY graph: Reciprocal relationship from REGN graph: Reciprocal relationship from ALNY graph: bal, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regene… |
| ACET | Adicet Bio, Inc. | 72% | Reciprocal relationship from ACET graph: f Shanghai Adicet from its then-stockholders (the Acquisition). In connection with the Acquisition, tax filings and registration were completed in August 2025… |
| ALLR | Allarity Therapeutics, Inc. | 72% | Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from REGN graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from REGN graph: Reciprocal relationship from ARTV g… |
| CELU | Celularity Inc. | 72% | Reciprocal relationship from CELU graph: . Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense categories of its consolidated statement of … |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS g… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CTMX graph: Squibb was evaluating the safety and efficacy of BMS-986288 alone and in com… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purpos… |
| GKOS | Glaukos Corporation | 72% | Reciprocal relationship from GKOS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from GKOS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from GKOS g… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in orde… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| IRIX | IRIDEX Corporation | 72% | Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, … |
| KLRS | Kalaris Therapeutics, Inc. | 72% | Reciprocal relationship from KLRS graph: or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There ar… |
| KNSA | Kiniksa Pharmaceuticals International, plc | 72% | Reciprocal relationship from KNSA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from KNSA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from KNSA g… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory r… |
| LNTH | Lantheus Holdings, Inc. | 72% | Reciprocal relationship from LNTH graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LNTH g… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone. HIV DART Molecules We conduct… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from NTLA g… |
| NUVB | Nuvation Bio Inc. | 72% | Reciprocal relationship from NUVB graph: Reciprocal relationship from REGN graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from REGN graph: Reciprocal relationship from NUVB g… |
| PBFS | Pioneer Bancorp, Inc. | 72% | Reciprocal relationship from PBFS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from PBFS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from PBFS g… |
| RCUS | Arcus Biosciences, Inc. | 72% | Reciprocal relationship from RCUS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to c… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that … |
| SNY | Sanofi | 72% | Reciprocal relationship from SNY graph: ns (such as the incremental cost of sales arising from the workdown of acquired inventories remeasured at fair value in business combinations) gives a better u… |
| SNYNF | Sanofi | 72% | ies can impose monetary penalties or other civil or criminal sanctions, including, among other things, refusal to approve a pending application for a new drug or biologic product, or revocation of a … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from REGN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from REGN graph: Reciprocal relationship from SNYN… |
| TBPH | Theravance Biopharma, Inc. | 72% | Reciprocal relationship from TBPH graph: Reciprocal relationship from REGN graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from REGN graph: Reciprocal relationship from TBPH g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DISTRIBUTOR-CUSTOMERS | DISTRIBUTOR-CUSTOMERS | 92% | We sell our marketed products for which we record net product sales in the United States to several distributors and specialty pharmacies, as applicable (collectively, "distributor customers"), which… |
| MAIA | MAIA Biotechnology, Inc. | 92% | Reciprocal relationship from MAIA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from MAIA graph: In February 2021, the Company entered into a Drug Supply Agreement (the “Dru… |
| NTLA | Intellia Therapeutics, Inc. | 90% | Reciprocal relationship from NTLA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from NTLA graph: we entered into a license and collaboration agreement with Regeneron |
| UPB | Upstream Bio, Inc. | 80% | Reciprocal relationship from UPB graph: Reciprocal relationship from REGN graph: Reciprocal relationship from UPB graph: Reciprocal relationship from REGN graph: Reciprocal relationship from UPB grap… |
| ALLR | Allarity Therapeutics, Inc. | 72% | Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimburs… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CTMX g… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from EDSA graph: Reciprocal relationship from REGN graph: Reciprocal relationship from EDSA g… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: ce with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adve… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements w… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| IRIX | IRIDEX Corporation | 72% | Reciprocal relationship from IRIX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from IRIX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from IRIX g… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LEGN g… |
| LLY | Eli Lilly and Company | 72% | on, patient education, reimbursement and market access, trade and distribution, commercial operations, commercial analytics, and market research. In addition, we also co-commercialize certain product… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LLY grap… |
| LNTH | Lantheus Holdings, Inc. | 72% | Reciprocal relationship from LNTH graph: Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2025 and 2024 - … |
| MCK | McKesson Corporation | 72% | Item 1A. "Risk Factors - Risks Related to Manufacturing and Supply" for further information. Among the conditions for marketing approval of a new drug or biologic product is the requirement that the … |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from REGN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from REGN graph: Item 1A. "Risk Factors - Risks Relate… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have significantly greater resources than we do. Furt… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from REGN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from REGN graph: Reciprocal relationship from MRK grap… |
| MRK | Merck & Co., Inc. | 72% | on, patient education, reimbursement and market access, trade and distribution, commercial operations, commercial analytics, and market research. In addition, we also co-commercialize certain product… |
| NUVB | Nuvation Bio Inc. | 72% | Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a lon… |
| NVSEF | Novartis AG | 72% | on, patient education, reimbursement and market access, trade and distribution, commercial operations, commercial analytics, and market research. In addition, we also co-commercialize certain product… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from REGN graph: on, patient education, reimbursement and market access, trade and distribution, commercial operations, commercial an… |
| OTLK | Outlook Therapeutics, Inc. | 72% | on, patient education, reimbursement and market access, trade and distribution, commercial operations, commercial analytics, and market research. In addition, we also co-commercialize certain product… |
| OTLK | Outlook Therapeutics, Inc. | 72% | Reciprocal relationship from OTLK graph: Reciprocal relationship from REGN graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from REGN graph: Reciprocal relationship from OTLK g… |
| RCUS | Arcus Biosciences, Inc. | 72% | Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufa… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from RGNX g… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| REGN-DEBT | Debt stack $3.5B | 90% | Market cache reports total debt of $3.5B. |
| REGN-DEBT-7339 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2016-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| REGN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 1403 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CMMB | Chemomab Therapeutics Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CVS | CVS Health Corporation | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CHKP | Check Point Software Technologies Ltd. | 100.00 | 1 | ['customer'] |
| AZN | AstraZeneca PLC | 100.00 | 2 |